Last reviewed · How we verify
NCT06342687
Compliance With ERAS and Five Year Survival After Colorectal Cancer Treatment
trial testing High compliance with ERAS protocol in Colorectal Cancer in 468 participants. Completed in 31 December 2023.
31 December 2022
Quick facts
| Lead sponsor | Jagiellonian University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 468 |
| Start date | 1 January 2018 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- High compliance with ERAS protocol
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- ERAS — all drugs for ERAS →
Sponsor
Jagiellonian University
Who can join
18 and older, any sex, with Colorectal Cancer or ERAS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Enhanced Recovery after Surgery (ERAS) protocol has transformed perioperative care, representing a significant paradigm shift in managing colorectal cancer patients. While the immediate benefits of Enhanced Recovery After Surgery (ERAS) in expediting postoperative recovery are well-documented and widely acknowledged, it is essential to investigate its long-term implications, particularly its influence on survival rates. The aim of this study will be to analyse the impact of compliance with the ERAS protocol on long- term outcomes after laparoscopic colorectal resection.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06342687
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Jagiellonian University trials
Trials by the same sponsor.
- NCT07410767 — Advanced Endoscopic Resections for Rectal Neoplasms · not yet recruiting
- NCT07364864 — Opioid-free Anesthesia as an Alternative to General Anesthesia in Patients Undergoing Duodenopancreatic Surgery by Lapar · NA · not yet recruiting
- NCT07378189 — Opioid-free Anesthesia as an Alternative to General Anesthesia in Patients Undergoing Laparoscopic Peripheral Pancreatic · NA · not yet recruiting
- NCT07389564 — Nationwide Registry of Patients With Heart Failure With Improved and Supranormal Ejection Fraction · active not recruiting
- NCT07306689 — Posttraumatic Stress Disorder in Ectopic Pregnancy · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06342687 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jagiellonian University
- Last refreshed: 2 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06342687.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing